AC
EBS icon

AXQ Capital’s Emergent Biosolutions EBS Stock Holding History

AXQ Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Buy
18,265
+1,261
+7% +$10.6K 0.02% 759
2026
Q1 		$141K Buy
17,004
+3,828
+29% +$39.6K 0.02% 822
2025
Q4 		$163K Buy
+13,176
New +$141K 0.04% 603
2023
Q3 		– Sell
-10,100
Closed -$74.2K – 507
2023
Q2 		$74.2K Sell
10,100
-12,039
-54% -$112K 0.09% 253
2023
Q1 		$229K Buy
+22,139
New +$268K 0.09% 375

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

AXQ Capital's EBS Position: Q2 2026 in Review

AXQ Capital increased its Emergent Biosolutions (EBS) stake by 7.4% in Q2 2026, buying an estimated $10.6K and bringing the position to 18,265 shares worth $153K. The position accounts for 0.02% of the portfolio, ranked #759.

AXQ Capital first reported a position in EBS in Q1 2023 and has held it in 5 quarters since. The position peaked at $229K in Q1 2023. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • AXQ Capital held 18,265 shares of Emergent Biosolutions worth $153K as of Q2 2026.
  • AXQ Capital bought 1,261 Emergent Biosolutions shares in Q2 2026, an estimated $10.6K.
  • Emergent Biosolutions made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #759 holding.
  • AXQ Capital first reported a position in Emergent Biosolutions in Q1 2023 and has held it in 5 quarters since.
  • AXQ Capital's Emergent Biosolutions position peaked at $229K in Q1 2023.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.